关键词:

急性髓性白血病, PTP4A3, 预后

Abstract:

Objective　To investigate the expression level of PTP4A3 in patients with acute myeloid leukemia (AML) and its correlation with clinical characteristics, relapse, and prognosis. Methods　From January 2019 to December 2020, 79 patients newly diagnosed with AML who took the whole process treatment at Zhongshan People's Hospital were selected as the study objects, including 40 males and 39 females, with a median age of 58. The bone marrow samples were collected before treatment to detect the PTP4A3 expression by quantitative real-time polymerase chain reaction (qRT-PCR). The patients were divided into high- and low-expression groups based on the median PTP4A3 expression level. The relationships of PTP4A3 with the patients' age, gender, ELN risk degree, and prognosis were analyzed. The Kaplan-Meier survival analysis and Cox proportional hazards model were used to analyzed the factors influencing their prognosis. χ² test was used for the statistical analysis. Results　High PTP4A3 expression was associated with age ≥60 years (P=0.017). The relapse rate in the high-expression group was higher than that in the low-expression group [47.50% (19/40) vs. 2.56% (1/39); P<0.001]. The survival analysis revealed a median survival time of 317 d in the high-expression group. The multivariate Cox analysis indicated that age ≥60 years (HR=5.422, P=0.020) and high PTP4A3 expression (HR=4.377, P=0.027) were the independent risk factors for AML relapse. Conclusion　High PTP4A3 expression is closely linked to increased relapse risk and poor prognosis in patients with AML, suggesting its potential as an independent prognostic biomarker and therapeutic target for AML.

Key words:

Acute myeloid leukemia, PTP4A3, Prognosis